Napa Wealth Management Purchases New Shares in Boston Scientific Corporation $BSX

Key Points

• Napa Wealth Management has acquired 7,340 shares of Boston Scientific Corporation, valued at approximately $740,000, during the first quarter.
• Institutional investors own 89.07% of Boston Scientific’s stock, with major stake increases reported from several firms such as Bank Pictet & Cie Europe AG and Brighton Jones LLC.
• The company reported a quarterly earnings per share of $0.75, exceeding analysts' expectations, with revenues of $5.06 billion, up 22.8% year-over-year.

Napa Wealth Management bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 7,340 shares of the medical equipment provider's stock, valued at approximately $740,000.

Several other institutional investors have also recently made changes to their positions in BSX. Colonial Trust Co SC grew its position in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 260 shares during the period. Investment Management Corp VA ADV bought a new position in Boston Scientific during the fourth quarter valued at about $25,000. Sunbeam Capital Management LLC bought a new position in Boston Scientific during the fourth quarter valued at about $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific during the first quarter valued at about $27,000. Finally, Ameriflex Group Inc. bought a new position in Boston Scientific during the fourth quarter valued at about $31,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Price Performance

NYSE BSX traded down $0.45 on Wednesday, reaching $105.94. 5,706,463 shares of the company's stock traded hands, compared to its average volume of 7,526,416. Boston Scientific Corporation has a 12 month low of $79.03 and a 12 month high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock has a 50-day simple moving average of $104.27 and a 200 day simple moving average of $102.15. The stock has a market cap of $156.98 billion, a PE ratio of 63.06, a P/E/G ratio of 2.53 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the business earned $0.62 earnings per share. The business's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at $18,347,824.96. This represents a 24.02% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on BSX. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Oppenheimer increased their target price on shares of Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a research report on Thursday, July 24th. Leerink Partners began coverage on shares of Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 target price for the company. Morgan Stanley increased their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. Finally, Citigroup reiterated a "buy" rating and set a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.